Additionally, viral vector-based gene therapies, such as adeno-associated virus (AAV)-mediated delivery of therapeutic genes, are showing potential in restoring lysosomal function in patients with PD with GBA mutations [116]. This evidence concerns the gene GBA1 and Parkinson disease.